Brief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
08/09/2026 13:09
BRIEF-Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema Sept 8 (Reuters) - BioAge Labs, Inc. BIOA.O:
BIOAGE LABS ANNOUNCES FIRST PARTICIPANT DOSED IN QUELL-DME, A PHASE 2 TRIAL OF BGE-102, A NOVEL ORAL NLRP3 INHIBITOR, IN DIABETIC MACULAR EDEMA
BIOAGE LABS - TOPLINE RESULTS FROM QUELL-DME TRIAL EXPECTED IN SECOND HALF OF 2027
Source text: ID:nGNX3M59Gf
Further company coverage: BIOA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioAge Labs
See all newsBrief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP